Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of STN1013400 ophthalmic solution in pediatric myopia
jRCT2031230110Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of STN1013400 in myopia (3 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Change in objective spherical equivalent. Started May 2023; status: completed.
02
Drugs
STN1013400
03
Conditions
myopia
Beyond the preview
Go deeper on jRCT2031230110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230110.